Literature DB >> 19929030

Epidemiology of suboptimal prescribing in older, community dwellers: a two-wave, population-based survey in Dicomano, Italy.

Francesco Lapi1, Claudia Pozzi, Giampiero Mazzaglia, Andrea Ungar, Stefano Fumagalli, Niccolò Marchionni, Pierangelo Geppetti, Alessandro Mugelli, Mauro Di Bari.   

Abstract

BACKGROUND: Because of co-morbidity, older persons are often exposed to use of an excessive number of drugs, which per se implies also use of inappropriate drugs or of potentially interacting drugs ('suboptimal prescribing'). Time trends of suboptimal prescribing in older, community dwellers have been poorly investigated, particularly in Italy.
OBJECTIVE: To evaluate the time-course modification of suboptimal prescribing in older, community dwellers.
METHODS: We conducted a study on an Italian cohort of older (aged>or=65 years), community dwellers for whom data were collected in a two-wave (1995 and 1999), population-based survey. Suboptimal prescribing was defined as occurrence of polypharmacy (>or=5 medications), prescription of inappropriate medications (according to 1991 Beers' criteria) and prescription of potentially interacting drugs (as identified by the Micromedex Drug-Reax system). All outcome variables were modelled as continuous and dichotomous.
RESULTS: In 568 participants (59.9% women, mean+/-standard error age 72.7+/-0.2 years), polypharmacy and potentially interacting drugs were more prevalent in 1999 than in 1995, while prevalence of inappropriate drugs was lower in 1999. The proportion of participants receiving polypharmacy was nearly 3-fold greater in 1999 than in 1995 (21.6% vs 8.8%; p<0.001). After adjustment for disability, coronary artery disease/stroke, heart failure and other co-morbidities, polypharmacy was twice as prevalent in 1999 as in 1995, with a mean increase of 0.5 drugs per participant. In contrast, in models adjusted for the same variables and also for polypharmacy, inappropriate prescribing was reduced (60% lower prevalence, 0.06 mean reduction in prescriptions per participant) in 1999 compared with 1995. In multivariable models, no change was observed in the number of potentially interacting prescriptions.
CONCLUSIONS: Between 1995 and 1999, the number of prescriptions received by a cohort of older, community dwellers increased substantially, even after controlling for co-morbidity. On the other hand, when controlling for polypharmacy, other indicators of suboptimal prescribing remained unaffected or even decreased, suggesting that even increasing levels of polypharmacy do not necessarily imply other forms of suboptimal prescribing among older persons.

Entities:  

Mesh:

Year:  2009        PMID: 19929030     DOI: 10.2165/11319390-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  30 in total

1.  Validation of self-reported chronic conditions and health services in a managed care population.

Authors:  L M Martin; M Leff; N Calonge; C Garrett; D E Nelson
Journal:  Am J Prev Med       Date:  2000-04       Impact factor: 5.043

Review 2.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.

Authors:  A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

Review 3.  Aging biology and geriatric clinical pharmacology.

Authors:  Allan J McLean; David G Le Couteur
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

Review 4.  Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine.

Authors:  M H Beers; J G Ouslander; I Rollingher; D B Reuben; J Brooks; J C Beck
Journal:  Arch Intern Med       Date:  1991-09

5.  Screening recommendations for the elderly.

Authors:  M H Beers; A Fink; J C Beck
Journal:  Am J Public Health       Date:  1991-09       Impact factor: 9.308

6.  Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems.

Authors:  Kirsten K Viktil; Hege S Blix; Tron A Moger; Aasmund Reikvam
Journal:  Br J Clin Pharmacol       Date:  2006-08-30       Impact factor: 4.335

7.  Use computers to detect inappropriate prescriptions.

Authors:  C Valentine
Journal:  BMJ       Date:  1993-07-03

8.  Impact of inappropriate drug use among hospitalized older adults.

Authors:  Graziano Onder; Francesco Landi; Rosa Liperoti; Daniela Fialova; Giovanni Gambassi; Roberto Bernabei
Journal:  Eur J Clin Pharmacol       Date:  2005-05-24       Impact factor: 2.953

9.  Predictive validity of measures of comorbidity in older community dwellers: the Insufficienza Cardiaca negli Anziani Residenti a Dicomano Study.

Authors:  Mauro Di Bari; Adriana Virgillo; Daniela Matteuzzi; Marco Inzitari; Giampiero Mazzaglia; Claudia Pozzi; Pierangelo Geppetti; Giulio Masotti; Niccolò Marchionni; Riccardo Pini
Journal:  J Am Geriatr Soc       Date:  2006-02       Impact factor: 5.562

10.  Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy.

Authors:  J J Gagne; V Maio; C Rabinowitz
Journal:  J Clin Pharm Ther       Date:  2008-04       Impact factor: 2.512

View more
  18 in total

1.  Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study.

Authors:  Wan-Hsuan Lu; Yu-Wen Wen; Liang-Kung Chen; Fei-Yuan Hsiao
Journal:  CMAJ       Date:  2015-02-02       Impact factor: 8.262

2.  Optimizing elderly pharmacotherapy: polypharmacy vs. undertreatment. Are these two concepts related?

Authors:  Encarnación Blanco-Reina; Gabriel Ariza-Zafra; Ricardo Ocaña-Riola; Matilde León-Ortíz; Inmaculada Bellido-Estévez
Journal:  Eur J Clin Pharmacol       Date:  2014-11-09       Impact factor: 2.953

3.  Variation over time in the association between polypharmacy and mortality in the older population.

Authors:  Kathryn Richardson; Alexandrine Ananou; Louise Lafortune; Carol Brayne; Fiona E Matthews
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

Review 4.  Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use?

Authors:  Giuseppe Sergi; Marina De Rui; Silvia Sarti; Enzo Manzato
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

5.  Inappropriate prescribing for the elderly--a modern epidemic?

Authors:  Gunhild Nyborg; Jørund Straand; Mette Brekke
Journal:  Eur J Clin Pharmacol       Date:  2012-02-15       Impact factor: 2.953

6.  [Prevalence of multiple medication and cardiovascular risk in patients over 65 years].

Authors:  Teresa Molina López; María de la O Caraballo Camacho; Daniel Palma Morgado; Soledad López Rubio; Juan Carlos Domínguez Camacho; Juan Carlos Morales Serna
Journal:  Aten Primaria       Date:  2011-09-15       Impact factor: 1.137

7.  The associations of geriatric syndromes and other patient characteristics with the current and future use of potentially inappropriate medications in a large cohort study.

Authors:  Dana Clarissa Muhlack; Liesa Katharina Hoppe; Christian Stock; Walter E Haefeli; Hermann Brenner; Ben Schöttker
Journal:  Eur J Clin Pharmacol       Date:  2018-08-29       Impact factor: 2.953

Review 8.  The patterns and implications of potentially suboptimal medicine regimens among older adults: a narrative review.

Authors:  Georgie B Lee; Christopher Etherton-Beer; Sarah M Hosking; Julie A Pasco; Amy T Page
Journal:  Ther Adv Drug Saf       Date:  2022-07-04

Review 9.  Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review.

Authors:  Eline Tommelein; Els Mehuys; Mirko Petrovic; Annemie Somers; Pieter Colin; Koen Boussery
Journal:  Eur J Clin Pharmacol       Date:  2015-09-26       Impact factor: 2.953

10.  Prevalence and Risk of Polypharmacy among Community-Dwelling, Elderly Kuwaiti Patients.

Authors:  Nabil Ahmed Badawy; Shokria Adely Labeeb; Mawaheb Falah Alsamdan; Badria Faleh Alazemi
Journal:  Med Princ Pract       Date:  2019-09-11       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.